Norinchukin Bank The boosted its holdings in Abbott Laboratories (NYSE:ABT) by 4.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 209,696 shares of the healthcare product maker’s stock after acquiring an additional 8,898 shares during the quarter. Norinchukin Bank The’s holdings in Abbott Laboratories were worth $10,193,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. DE Burlo Group Inc. bought a new stake in Abbott Laboratories in the first quarter valued at about $213,000. Thomaspartners Inc. increased its stake in Abbott Laboratories by 10.3% in the first quarter. Thomaspartners Inc. now owns 5,099,993 shares of the healthcare product maker’s stock valued at $226,491,000 after acquiring an additional 475,033 shares during the period. Karp Capital Management Corp bought a new stake in Abbott Laboratories in the first quarter valued at about $32,885,000. First Foundation Advisors grew its stake in Abbott Laboratories by 2.1% during the first quarter. First Foundation Advisors now owns 13,588 shares of the healthcare product maker’s stock worth $603,000 after buying an additional 283 shares during the last quarter. Finally, Baker Chad R bought a new stake in Abbott Laboratories during the first quarter worth about $3,220,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Sharon J. Bracken sold 2,188 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $56.12, for a total value of $122,790.56. Following the transaction, the insider now directly owns 25,618 shares in the company, valued at $1,437,682.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the transaction, the insider now owns 58,739 shares in the company, valued at $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold 311,127 shares of company stock worth $16,958,579 over the last three months. 0.76% of the stock is owned by insiders.

Several brokerages have weighed in on ABT. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Jefferies Group reaffirmed a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research note on Thursday, October 19th. Royal Bank Of Canada upped their price objective on shares of Abbott Laboratories from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Cowen set a $68.00 price objective on shares of Abbott Laboratories and gave the stock a “buy” rating in a research note on Thursday, October 19th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $56.81.

Shares of Abbott Laboratories (ABT) opened at $54.66 on Thursday. Abbott Laboratories has a 52 week low of $37.42 and a 52 week high of $56.69. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The company has a market cap of $95,367.53, a P/E ratio of 22.73, a PEG ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year. analysts anticipate that Abbott Laboratories will post 2.49 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were paid a dividend of $0.265 per share. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.94%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 83.47%.

COPYRIGHT VIOLATION WARNING: “Norinchukin Bank The Has $10.19 Million Position in Abbott Laboratories (ABT)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/norinchukin-bank-the-has-10-19-million-position-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.